Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 15/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 15/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 15/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 15/20 | 1.00 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.47 |
| ▸ | TUBB | P07437 | 1/20 | 0.47 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.47 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.47 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.47 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.47 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.47 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.47 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.47 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.47 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.47 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.47 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.47 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.47 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Awd-12-281 SCHEMBL29413256 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DTUBB4A | |
| Awd-12-281 SCHEMBL5638122 | 0.99 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DTUBB4A | |
| Awd-12-281 SCHEMBL5638136 | 0.99 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DTUBB4A | |
| SCHEMBL3101476 | 0.94 | PDE4A (0.89) | PDE4APDE4BPDE4CPDE4DTUBB4A | |
| SCHEMBL6255980 | 0.94 | PDE4A (0.89) | PDE4APDE4BPDE4CPDE4DTUBB4A | |
| SCHEMBL5637675 | 0.92 | PDE4A (0.85) | PDE4APDE4BPDE4CPDE4DTUBB4A | |
| SCHEMBL5637676 | 0.90 | PDE4A (0.82) | PDE4APDE4BPDE4CPDE4DTUBB4A | |
| SCHEMBL27554475 | 0.89 | PDE4A (0.81) | PDE4APDE4BPDE4CPDE4DTUBB4A | |
| SCHEMBL28618046 | 0.89 | PDE4A (0.80) | PDE4APDE4BPDE4CPDE4DTUBB4A | |
| SCHEMBL5636873 | 0.88 | PDE4A (0.78) | PDE4APDE4BPDE4CPDE4DPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1755 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119303086-A | Pharmaceutical composition for treating autism | 斯塔利克拉股份有限公司 | 2025-01-14 | — | — | CN | claimed |
| US-20240316015-A1 | COMPOSITION AND METHOD FOR TREATING TUMORS | NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) | 2024-09-26 | — | — | US | claimed |
| EP-4282413-A1 | COMPOSITION AND METHOD FOR TREATING TUMORS | NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) | 2023-11-29 | — | — | EP | claimed |
| CN-116963773-A | Compositions and methods for treating tumors | 浙江养生堂天然药物研究所有限公司 | 2023-10-27 | — | — | CN | claimed |
| US-20230338345-A1 | DRUG COMBINATION AND USE THEREOF | NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) | 2023-10-26 | — | — | US | claimed |
| EP-4140480-A1 | DRUG COMBINATION AND USE THEREOF | NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) | 2023-03-01 | — | — | EP | claimed |
| CN-115397411-A | Pharmaceutical combination and use thereof | 浙江养生堂天然药物研究所有限公司 | 2022-11-25 | — | — | CN | claimed |
| US-11439627-B2 | Pharmaceutical composition for the treatment of autism | Stalicla S.A. (CH) | 2022-09-13 | — | — | US | claimed |
| WO-2022156727-A1 | COMPOSITION AND METHOD FOR TREATING TUMORS | 浙江养生堂天然药物研究所有限公司 | 2022-07-28 | — | — | WO | claimed |
| EP-3958847-A2 | INHALATION COMPOSITIONS COMPRISING PHOSPHODIESTERASE-4 INHIBITOR | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi (TR) | 2022-03-02 | — | — | EP | claimed |
| US-6545158-B2 | Such as N-(3,5-dichloropyridin-4-yl)-2-(1-(4-fluorobenzyl)-5-hydroxyindol-3-yl)-2 -oxoacetamide; for treatment of eosinophil-related disorders and chronic obstructive pulmonary disease | ARZNEIMITTELWERK DRESDEN GMBH (DE) | 2003-04-08 | — | — | US | claimed |
| US-6545025-B2 | Hydroxyindoles, their use as inhibitors of phosphodiesterase 4 and processes for their preparation | ARZNEIMITTELWERK DRESDEN GMBH (DE) | 2003-04-08 | — | — | US | claimed |
| WO-2003024489-A2 | COMBINATION OF A NSAID AND A PDE-4 INHIBITOR | ALTANA PHARMA AG (DE) | 2003-03-27 | — | — | WO | claimed |
| WO-2003024488-A2 | COMBINATION OF A PDE INHIBITOR AND A LEUKOTRIENE RECEPTOR ANTAGONIST | ALTANA PHARMA AG (DE) | 2003-03-27 | — | — | WO | claimed |
| US-20020137745-A1 | N-(3,5-dichloropyridin-4-yl)-2-(1-(4-fluorobenzyl)-5 -hydroxyindol-3-yl)-2-oxoacetamide, for example; treating eosinophil-related conditions, including chronic obstructive pulmonary disease | ELBION AG (DE) | 2002-09-26 | — | — | US | claimed |
| US-20020119971-A1 | Antiinflammatory agents; skin disorders; central nervous system disorders | ELBION AG (DE) | 2002-08-29 | — | — | US | claimed |
| US-20020115651-A1 | Such as N-(3,5-dichloropyridin-4-yl)-2-(1-(4-fluorobenzyl)-5-hydroxyindol-3-yl)-2 -oxoacetamide; for treatment of eosinophil-related disorders and chronic obstructive pulmonary disease | ELBION AG (DE) | 2002-08-22 | — | — | US | claimed |
| US-20020111351-A1 | Antiinflammatroy agents; antiallergens | ELBION AG (DE) | 2002-08-15 | — | — | US | claimed |
| CN-1307575-A | Novel hydroxyindoles, their use as phosphodiesterase 4 inhibitors and process for their preparation | DRESDEN ARZNEIMITTEL (DE) | 2001-08-08 | — | — | CN | claimed |
| US-6251923-B1 | Hydroxyindoles, their use as inhibitors of phosphodiesterase 4 and process for their preparation | ARZNEIMITTELWERK DRESDEN GMBH (DE) | 2001-06-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111351-A1 | Antiinflammatroy agents; antiallergens | MPO, LTA4H, PADI4 | PDE4A 8/4885PDE4B 17/4885PDE4C 49/4885 |
| US-20020119971-A1 | Antiinflammatory agents; skin disorders; central nervous system disorders | PDE4A, TPH1, PDE12 | PDE4A 1/4885PDE4B 4/4885PDE4C 7/4885 |
| US-20020115651-A1 | Such as N-(3,5-dichloropyridin-4-yl)-2-(1-(4-fluorobenzyl)-5-hydroxyindol-3-yl)-2 -oxoacetamide; for treatment of eosinophil-related disorders and chronic obstructive pulmonary disease | EPX, SERPINB1, ELANE | PDE4A 5/4885PDE4B 7/4885PDE4C 14/4885 |
| US-20240316015-A1 | COMPOSITION AND METHOD FOR TREATING TUMORS | PDE4B, PDE4A, PDE4C | PDE4A 2/4885PDE4B 1/4885PDE4C 3/4885 |
| US-20020137745-A1 | N-(3,5-dichloropyridin-4-yl)-2-(1-(4-fluorobenzyl)-5 -hydroxyindol-3-yl)-2-oxoacetamide, for example; treating eosinophil-related conditions, including chronic obstructive pulmonary disease | EPX, CCL11, PDE12 | PDE4A 6/4885PDE4B 7/4885PDE4C 17/4885 |
| US-20230338345-A1 | DRUG COMBINATION AND USE THEREOF | PDE4B, PDE4A, ADH4 | PDE4A 2/4885PDE4B 1/4885PDE4C 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.